Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pranab Maiti

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|May 12, 2009
TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disordersAtul Tiwari, Pranab Maiti
Organic & Biomolecular Chemistry|December 11, 2003
Stereocontrol of 1,5-related stereocentres using an intermediate silyl group--the diastereoselectivity of nucleophilic attack on a double bond adjacent to a stereogenic centre carrying a silyl groupIan Fleming, Pranab Maiti, Chandrashekar Ramarao
Biochemistry|November 3, 2005
Specificity of binding of all-trans-retinyl ester to RPE65Pranab Maiti, Deviprasad Gollapalli, Robert R Rando
Biochemistry|October 8, 2003
RPE65 operates in the vertebrate visual cycle by stereospecifically binding all-trans-retinyl estersDeviprasad R Gollapalli, Pranab Maiti, Robert R Rando
Cell|June 10, 2004
A palmitoylation switch mechanism in the regulation of the visual cycleLinlong Xue, Deviprasad R Gollapalli, Pranab Maiti, et al.
Biochemistry|January 18, 2006
Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formationPranab Maiti, Jian Kong, So Ra Kim, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2018
Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagyArthur F Kluge, Bharat R Lagu, Pranab Maiti, et al.
Pharmacology Research & Perspectives|January 19, 2017
A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetesYanyun Chen, Min Song, Jonathan P Riley, et al.
Journal of Medicinal Chemistry|December 14, 2017
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes MellitusChafiq Hamdouchi, Pranab Maiti, Alan M Warshawsky, et al.
Journal of Medicinal Chemistry|October 18, 2016
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)Chafiq Hamdouchi, Steven D Kahl, Anjana Patel Lewis, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|May 12, 2009
TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disordersAtul Tiwari, Pranab Maiti
Organic & Biomolecular Chemistry|December 11, 2003
Stereocontrol of 1,5-related stereocentres using an intermediate silyl group--the diastereoselectivity of nucleophilic attack on a double bond adjacent to a stereogenic centre carrying a silyl groupIan Fleming, Pranab Maiti, Chandrashekar Ramarao
Biochemistry|November 3, 2005
Specificity of binding of all-trans-retinyl ester to RPE65Pranab Maiti, Deviprasad Gollapalli, Robert R Rando
Biochemistry|October 8, 2003
RPE65 operates in the vertebrate visual cycle by stereospecifically binding all-trans-retinyl estersDeviprasad R Gollapalli, Pranab Maiti, Robert R Rando
Cell|June 10, 2004
A palmitoylation switch mechanism in the regulation of the visual cycleLinlong Xue, Deviprasad R Gollapalli, Pranab Maiti, et al.
Biochemistry|January 18, 2006
Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formationPranab Maiti, Jian Kong, So Ra Kim, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2018
Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagyArthur F Kluge, Bharat R Lagu, Pranab Maiti, et al.
Pharmacology Research & Perspectives|January 19, 2017
A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetesYanyun Chen, Min Song, Jonathan P Riley, et al.
Journal of Medicinal Chemistry|December 14, 2017
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes MellitusChafiq Hamdouchi, Pranab Maiti, Alan M Warshawsky, et al.
Journal of Medicinal Chemistry|October 18, 2016
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)Chafiq Hamdouchi, Steven D Kahl, Anjana Patel Lewis, et al.
Pageof 1